Becton, Dickinson (BDX)
Becton, Dickinson on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, federal contracts, earnings dates and insider trades. Listed on NYSE, classified by the SEC as surgical & medical instruments & apparatus.
8.9M
Short interest
settlement 2026-10-15
5.5
Days to cover
+0.6 days vs prior
29.0%
Short share of volume
2026-11-02
2,869
Fails to deliver
settlement 2026-10-09
Thu 5 Nov
Next earnings
estimated date
-$1.3M
Insider flow, 90 days
0 buys, 5 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in BDX is 8,907,876 shares, down 2,408,361 shares over the last month. Over the last 48 readings it ranged from 1,895,383 shares (29 November 2024) to 14,558,496 shares (13 February 2026). At the reported average volume of 1.6M shares a day that is 5.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/bdx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 8,907,876 | -8.9% | 1,624,702 | 5.48 |
| 2026-09-30 | 9,775,719 | -13.6% | 2,002,996 | 4.88 |
| 2026-09-15 | 11,316,237 | +6.0% | 1,574,524 | 7.19 |
| 2026-08-31 | 10,672,859 | +13.9% | 1,744,334 | 6.12 |
| 2026-08-14 | 9,368,149 | -6.5% | 1,951,725 | 4.80 |
| 2026-07-31 | 10,015,223 | -3.5% | 1,747,386 | 5.73 |
| 2026-07-15 | 10,381,615 | -7.6% | 1,784,461 | 5.82 |
| 2026-06-30 | 11,236,246 | +54.4% | 3,874,971 | 2.90 |
| 2026-06-15 | 7,277,932 | +1.0% | 2,024,125 | 3.60 |
| 2026-05-29 | 7,204,143 | -14.4% | 2,983,849 | 2.41 |
| 2026-05-15 | 8,414,123 | +31.9% | 3,695,263 | 2.28 |
| 2026-04-30 | 6,377,860 | -11.6% | 3,111,006 | 2.05 |
| 2026-04-15 | 7,213,805 | -24.0% | 2,451,299 | 2.94 |
| 2026-03-31 | 9,492,557 | -17.2% | 2,279,841 | 4.16 |
| 2026-03-13 | 11,469,470 | -16.8% | 2,685,695 | 4.27 |
| 2026-02-27 | 13,780,778 | -5.3% | 2,929,566 | 4.70 |
| 2026-02-13 | 14,558,496 | +117.5% | 3,879,380 | 3.75 |
| 2026-01-30 | 6,692,313 | +10.3% | 1,940,008 | 3.45 |
| 2026-01-15 | 6,069,158 | +0.7% | 1,667,849 | 3.64 |
| 2025-12-31 | 6,029,622 | +25.4% | 1,886,610 | 3.20 |
| 2025-12-15 | 4,809,734 | +0.3% | 1,959,158 | 2.46 |
| 2025-11-28 | 4,794,887 | +14.7% | 2,035,476 | 2.36 |
| 2025-11-14 | 4,179,247 | +34.2% | 3,649,075 | 1.15 |
| 2025-10-31 | 3,113,440 | -5.1% | 2,139,834 | 1.45 |
| 2025-10-15 | 3,281,199 | -14.4% | 1,193,433 | 2.75 |
| 2025-09-30 | 3,834,780 | -10.5% | 1,432,721 | 2.68 |
| 2025-09-15 | 4,283,364 | -6.1% | 1,777,458 | 2.41 |
| 2025-08-29 | 4,560,898 | -11.9% | 1,700,999 | 2.68 |
| 2025-08-15 | 5,177,051 | -5.5% | 3,284,785 | 1.58 |
| 2025-07-31 | 5,479,761 | +17.0% | 2,652,964 | 2.07 |
| 2025-07-15 | 4,685,009 | +20.1% | 3,201,297 | 1.46 |
| 2025-06-30 | 3,901,285 | +21.4% | 3,068,374 | 1.27 |
| 2025-06-13 | 3,213,975 | +2.0% | 2,532,032 | 1.27 |
| 2025-05-30 | 3,150,063 | -3.4% | 2,460,727 | 1.28 |
| 2025-05-15 | 3,260,445 | -10.4% | 5,469,589 | 1.00 |
| 2025-04-30 | 3,640,769 | -10.6% | 2,125,675 | 1.71 |
| 2025-04-15 | 4,072,992 | +7.6% | 2,848,051 | 1.43 |
| 2025-03-31 | 3,785,656 | +31.8% | 2,044,905 | 1.85 |
| 2025-03-14 | 2,872,360 | -2.2% | 1,928,234 | 1.49 |
| 2025-02-28 | 2,935,970 | -21.1% | 1,629,902 | 1.80 |
| 2025-02-14 | 3,720,332 | +37.6% | 2,582,455 | 1.44 |
| 2025-01-31 | 2,704,427 | -21.9% | 1,821,588 | 1.48 |
| 2025-01-15 | 3,463,339 | -7.2% | 2,150,740 | 1.61 |
| 2024-12-31 | 3,730,990 | +42.0% | 2,066,504 | 1.81 |
| 2024-12-13 | 2,628,372 | +38.7% | 2,357,950 | 1.11 |
| 2024-11-29 | 1,895,383 | -10.2% | 1,676,761 | 1.13 |
| 2024-11-15 | 2,111,177 | +3.7% | 2,142,276 | 1.00 |
| 2024-10-31 | 2,036,596 | -15.6% | 922,506 | 2.21 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of BDX volume is 29.0%, down 0.7 points over the last five sessions. Over the last 30 readings it ranged from 20.8% (28 October 2026) to 57.8% (23 September 2026). The latest reading is 10.5 points below the 30-session average of 39.5%, on 634K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 184K | 634K | 29.0% | 393 |
| 2026-10-30 | 268K | 619K | 43.3% | 501 |
| 2026-10-29 | 424K | 1.1M | 40.3% | 337 |
| 2026-10-28 | 149K | 715K | 20.8% | 1 |
| 2026-10-27 | 149K | 475K | 31.4% | 105 |
| 2026-10-26 | 196K | 659K | 29.7% | 1,916 |
| 2026-10-23 | 212K | 507K | 41.8% | 76 |
| 2026-10-22 | 236K | 474K | 49.8% | 11,032 |
| 2026-10-21 | 240K | 441K | 54.5% | 9 |
| 2026-10-20 | 151K | 434K | 34.8% | 141 |
| 2026-10-19 | 171K | 415K | 41.2% | 432 |
| 2026-10-16 | 210K | 425K | 49.5% | 26 |
| 2026-10-15 | 267K | 872K | 30.7% | 1,325 |
| 2026-10-14 | 234K | 621K | 37.7% | 3 |
| 2026-10-13 | 223K | 487K | 45.7% | 50 |
| 2026-10-12 | 151K | 414K | 36.6% | 454 |
| 2026-10-09 | 147K | 377K | 38.9% | 45 |
| 2026-10-08 | 289K | 639K | 45.2% | 0 |
| 2026-10-07 | 272K | 761K | 35.8% | 167 |
| 2026-10-06 | 205K | 897K | 22.9% | 1,556 |
| 2026-10-05 | 163K | 630K | 25.9% | 45 |
| 2026-10-02 | 284K | 568K | 50.0% | 46,243 |
| 2026-10-01 | 178K | 429K | 41.4% | 228 |
| 2026-09-30 | 214K | 530K | 40.5% | 41 |
| 2026-09-29 | 240K | 540K | 44.4% | 476 |
| 2026-09-28 | 317K | 833K | 38.0% | 490 |
| 2026-09-25 | 224K | 640K | 35.0% | 53 |
| 2026-09-24 | 199K | 528K | 37.7% | 74 |
| 2026-09-23 | 248K | 429K | 57.8% | 94 |
| 2026-09-22 | 278K | 516K | 53.8% | 452 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 October 2026, the fails-to-deliver balance in BDX is 2,869 shares, up 2,697 shares over the last settlement date. Over the last 30 readings it ranged from 6 shares (27 August 2026) to 111,293 shares (29 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-09 | 2,869 | $182.75 | $524K |
| 2026-10-08 | 172 | $180.16 | $31K |
| 2026-10-07 | 5,828 | $180.30 | $1.1M |
| 2026-10-05 | 11,200 | $176.80 | $2.0M |
| 2026-09-21 | 1,691 | $180.94 | $306K |
| 2026-09-09 | 127 | $179.10 | $23K |
| 2026-09-04 | 2,217 | $187.62 | $416K |
| 2026-08-28 | 1,560 | $188.13 | $293K |
| 2026-08-27 | 6 | $190.21 | $1K |
| 2026-08-24 | 400 | $192.00 | $77K |
| 2026-08-12 | 76 | $181.41 | $14K |
| 2026-08-11 | 406 | $179.63 | $73K |
| 2026-08-07 | 5,775 | $177.07 | $1.0M |
| 2026-08-06 | 411 | $170.66 | $70K |
| 2026-08-05 | 467 | $170.12 | $79K |
| 2026-08-04 | 479 | $170.21 | $82K |
| 2026-08-03 | 449 | $165.62 | $74K |
| 2026-07-31 | 24,362 | $165.45 | $4.0M |
| 2026-07-30 | 22 | $168.40 | $4K |
| 2026-07-29 | 426 | $166.34 | $71K |
| 2026-07-27 | 19 | $156.36 | $3K |
| 2026-07-20 | 33,112 | $158.17 | $5.2M |
| 2026-07-17 | 12 | $159.93 | $2K |
| 2026-07-16 | 10,733 | $154.88 | $1.7M |
| 2026-07-07 | 46 | $155.54 | $7K |
| 2026-07-02 | 529 | $152.90 | $81K |
| 2026-06-30 | 63,258 | $155.19 | $9.8M |
| 2026-06-29 | 111,293 | $155.92 | $17.4M |
| 2026-06-23 | 61 | $140.71 | $9K |
| 2026-06-22 | 4,874 | $143.98 | $702K |
Insider trades
SEC Form 4, newest first. JSONInsiders at BDX reported 5 open-market sells worth $1.3M in the last 90 days and no open-market buys. Latest filing: Feld Michael (EVP, Chief Revenue Officer) on 2026-10-26.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-26 | Feld Michael | EVP, Chief Revenue Officer | Sell | 76 | $198.13 | $15K | 20K |
| 2026-09-28 | Feld Michael | EVP, Chief Revenue Officer | Sell | 76 | $183.70 | $14K | 20K |
| 2026-09-02 | Roque Vitor | EVP & Chief Financial Officer | Tax withholding | 190 | $0.00 | $0 | 8K |
| 2026-08-26 | Feld Michael | EVP, Chief Revenue Officer | Sell | 165 | $188.49 | $31K | 20K |
| 2026-08-20 | Feld Michael | EVP, Chief Revenue Officer | Tax withholding | 1K | $0.00 | $0 | 20K |
| 2026-08-13 | Polen Thomas E Jr | Chairman, CEO and President | Sell | 4K | $185.00 | $768K | 110K |
| 2026-08-13 | Polen Thomas E Jr | Chairman, CEO and President | Returned to company | 39K | $185.00 | $7.2M | 114K |
| 2026-08-13 | Polen Thomas E Jr | Chairman, CEO and President | Exercise or conversion | 43K | $167.25 | $7.2M | 153K |
| 2026-08-11 | Goette Roland | EVP and President, EMEA | Sell | 2K | $180.84 | $441K | 15K |
| 2026-07-27 | Feld Michael | EVP, Chief Revenue Officer | Sell | 75 | $157.13 | $12K | 21K |
| 2026-07-02 | Muhsin Bilal | EVP & President Connected Care | Tax withholding | 2K | $0.00 | $0 | 41K |
| 2026-07-01 | Muhsin Bilal | EVP & President Connected Care | Grant | 14K | $0.00 | $0 | 43K |
| 2026-06-26 | Feld Michael | EVP, Chief Revenue Officer | Sell | 75 | $152.80 | $11K | 21K |
| 2026-06-24 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Sell | 1K | $145.66 | $160K | 13K |
| 2026-06-10 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Sell | 1K | $151.48 | $167K | 14K |
| 2026-06-01 | Menziuso Peter | EVP and President, BDI | Grant | 14K | $0.00 | $0 | 14K |
| 2026-06-01 | Polen Thomas E Jr | Chairman, CEO and President | Sell | 3K | $146.35 | $405K | 110K |
| 2026-06-01 | Polen Thomas E Jr | Chairman, CEO and President | Returned to company | 17K | $146.15 | $2.5M | 108K |
| 2026-06-01 | Polen Thomas E Jr | Chairman, CEO and President | Exercise or conversion | 20K | $126.16 | $2.5M | 126K |
| 2026-05-26 | Feld Michael | EVP, Chief Revenue Officer | Sell | 75 | $147.35 | $11K | 21K |
| 2026-05-07 | Roque Vitor | EVP & Chief Financial Officer | Grant | 2K | $0.00 | $0 | 8K |
| 2026-04-27 | Feld Michael | EVP, Chief Revenue Officer | Sell | 74 | $151.94 | $11K | 21K |
| 2026-04-06 | Neal Shana Carol | EVP and Chief People Officer | Tax withholding | 1K | $0.00 | $0 | 24K |
| 2026-03-26 | Feld Michael | EVP, Chief Revenue Officer | Sell | 75 | $156.83 | $12K | 21K |
| 2026-03-16 | Minnix Lanesha | EVP and General Counsel | Grant | 7K | $0.00 | $0 | 7K |
| 2026-03-02 | Roque Vitor | Interim CFO | Grant | 931 | $0.00 | $0 | 7K |
| 2026-03-02 | Spikner Pamela L. | SVP Controller & CAO | Grant | 931 | $0.00 | $0 | 3K |
| 2026-02-26 | Feld Michael | EVP, Chief Revenue Officer | Sell | 75 | $181.84 | $14K | 21K |
| 2026-02-18 | SCOTT BERTRAM L | Director | Sell | 953 | $182.61 | $174K | 37K |
| 2026-01-27 | Henderson Jeffrey William | Director | Grant | 1K | $0.00 | $0 | 9K |
| 2026-01-27 | ECKERT R ANDREW | Director | Grant | 1K | $0.00 | $0 | 10K |
| 2026-01-27 | Byington Carrie L | Director | Grant | 1K | $0.00 | $0 | 5K |
| 2026-01-27 | HAYES GREGORY | Director | Grant | 1K | $0.00 | $0 | 7K |
| 2026-01-27 | Brown William M | Director | Grant | 1K | $0.00 | $0 | 5K |
| 2026-01-27 | Huffines Robert Luther | Director | Grant | 1K | $0.00 | $0 | 1K |
| 2026-01-27 | Jones Christopher Ian Montague | Director | Grant | 1K | $0.00 | $0 | 24K |
| 2026-01-27 | RING TIMOTHY M | Director | Grant | 1K | $0.00 | $0 | 59K |
| 2026-01-27 | SCOTT BERTRAM L | Director | Grant | 1K | $0.00 | $0 | 38K |
| 2026-01-27 | Waldstreicher Joanne | Director | Grant | 1K | $0.00 | $0 | 3K |
| 2026-01-27 | Wright Jacqueline | Director | Grant | 1K | $0.00 | $0 | 1K |
| 2026-01-26 | Feld Michael | EVP, CRO & Pres. Life Sciences | Sell | 75 | $202.73 | $15K | 16K |
| 2026-01-21 | Spikner Pamela L. | SVP Controller & CAO | Tax withholding | 84 | $0.00 | $0 | 2K |
| 2026-01-15 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Sell | 1K | $206.54 | $209K | 12K |
| 2026-01-15 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Sell | 600 | $209.00 | $125K | 13K |
| 2026-01-15 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Returned to company | 2K | $209.00 | $513K | 14K |
| 2026-01-15 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Exercise or conversion | 3K | $167.91 | $513K | 16K |
| 2026-01-03 | Shan David | EVP and Chief ISC Officer | Tax withholding | 44 | $0.00 | $0 | 9K |
| 2025-12-26 | Feld Michael | EVP, CRO & Pres. Life Sciences | Sell | 74 | $196.08 | $15K | 17K |
| 2025-12-17 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Sell | 629 | $196.03 | $123K | 13K |
| 2025-12-01 | Feld Michael | EVP, CRO & Pres. Life Sciences | Sell | 75 | $193.36 | $15K | 17K |
| 2025-12-01 | Wright Jacqueline | Director | Grant | 180 | $0.00 | $0 | 180 |
| 2025-12-01 | Huffines Robert Luther | Director | Grant | 180 | $0.00 | $0 | 180 |
| 2025-11-26 | Mocherla Pavan Kumar | EVP & President, Greater Asia | Grant | 708 | $0.00 | $0 | 6K |
| 2025-11-26 | Mocherla Pavan Kumar | EVP & President, Greater Asia | Grant | 2K | $0.00 | $0 | 5K |
| 2025-11-26 | Shan David | EVP and Chief ISC Officer | Tax withholding | 134 | $0.00 | $0 | 9K |
| 2025-11-26 | Shan David | EVP and Chief ISC Officer | Grant | 1K | $0.00 | $0 | 9K |
| 2025-11-26 | Shan David | EVP and Chief ISC Officer | Grant | 4K | $0.00 | $0 | 8K |
| 2025-11-26 | Neal Shana Carol | EVP and Chief People Officer | Tax withholding | 2K | $0.00 | $0 | 21K |
| 2025-11-26 | Neal Shana Carol | EVP and Chief People Officer | Grant | 4K | $0.00 | $0 | 24K |
| 2025-11-26 | Neal Shana Carol | EVP and Chief People Officer | Grant | 7K | $0.00 | $0 | 20K |
| 2025-11-26 | Goette Roland | EVP and President, EMEA | Tax withholding | 138 | $0.00 | $0 | 17K |
| 2025-11-26 | Goette Roland | EVP and President, EMEA | Grant | 1K | $0.00 | $0 | 17K |
| 2025-11-26 | Goette Roland | EVP and President, EMEA | Grant | 2K | $0.00 | $0 | 16K |
| 2025-11-26 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Tax withholding | 2K | $0.00 | $0 | 14K |
| 2025-11-26 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Grant | 3K | $0.00 | $0 | 16K |
| 2025-11-26 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Grant | 8K | $0.00 | $0 | 12K |
| 2025-11-26 | Feld Michael | EVP, CRO & Pres. Life Sciences | Tax withholding | 419 | $0.00 | $0 | 17K |
| 2025-11-26 | Feld Michael | EVP, CRO & Pres. Life Sciences | Grant | 9K | $0.00 | $0 | 17K |
| 2025-11-26 | DelOrefice Christopher | EVP & Chief Financial Officer | Tax withholding | 4K | $0.00 | $0 | 23K |
| 2025-11-26 | DelOrefice Christopher | EVP & Chief Financial Officer | Grant | 6K | $0.00 | $0 | 27K |
| 2025-11-26 | Byrd Richard | EVP & President Interventional | Tax withholding | 2K | $0.00 | $0 | 14K |
| 2025-11-26 | Byrd Richard | EVP & President Interventional | Grant | 2K | $0.00 | $0 | 16K |
| 2025-11-26 | Byrd Richard | EVP & President Interventional | Grant | 6K | $0.00 | $0 | 13K |
| 2025-11-26 | Muhsin Bilal | EVP & President Connected Care | Grant | 10K | $0.00 | $0 | 22K |
| 2025-11-26 | Polen Thomas E Jr | Chairman, CEO and President | Tax withholding | 17K | $0.00 | $0 | 105K |
| 2025-11-26 | Polen Thomas E Jr | Chairman, CEO and President | Grant | 23K | $0.00 | $0 | 123K |
| 2025-11-26 | Spikner Pamela L. | SVPController & Chief Acct Off | Grant | 1K | $0.00 | $0 | 2K |
| 2025-11-07 | SCOTT BERTRAM L | Director | Sell | 217 | $176.58 | $38K | 36K |
| 2025-10-27 | Feld Michael | EVP & President, Life Sciences | Sell | 57 | $186.01 | $11K | 8K |
| 2025-09-26 | Feld Michael | EVP & President, Life Sciences | Sell | 58 | $181.03 | $10K | 8K |
| 2025-09-10 | Fraser Claire | Director | Sell | 917 | $187.50 | $172K | 22K |
| 2025-09-01 | DelOrefice Christopher | EVP & Chief Financial Officer | Tax withholding | 278 | $0.00 | $0 | 21K |
| 2025-09-01 | Byrd Richard | EVP & President Interventional | Tax withholding | 216 | $0.00 | $0 | 7K |
| 2025-08-22 | Feld Michael | EVP & President, Life Sciences | Sell | 57 | $197.99 | $11K | 8K |
| 2025-08-20 | Feld Michael | EVP & President, Life Sciences | Tax withholding | 773 | $0.00 | $0 | 8K |
| 2025-08-11 | HAYES GREGORY | Director | Buy | 5K | $191.57 | $1.0M | 6K |
| 2025-08-08 | Fraser Claire | Director | Sell | 863 | $192.30 | $166K | 23K |
| 2025-07-18 | Garrison Michael David | EVP & President, Medical | Sell | 1 | $181.50 | $182 | 5K |
| 2025-07-18 | Garrison Michael David | EVP & President, Medical | Sell | 1K | $180.29 | $213K | 5K |
| 2025-07-18 | Garrison Michael David | EVP & President, Medical | Returned to company | 5K | $180.29 | $933K | 6K |
| 2025-07-18 | Garrison Michael David | EVP & President, Medical | Exercise or conversion | 6K | $147.68 | $939K | 11K |
| 2025-07-02 | Muhsin Bilal | EVP & President Connected Care | Grant | 12K | $0.00 | $0 | 12K |
| 2025-06-02 | Shan David | EVP and Chief ISC Officer | Sell | 1K | $171.19 | $200K | 5K |
| 2025-04-09 | Garrison Michael David | EVP & President, Medical | Sell | 479 | $197.28 | $94K | 5K |
| 2025-04-04 | Neal Shana Carol | EVP and Chief People Officer | Tax withholding | 2K | $0.00 | $0 | 14K |
| 2025-03-26 | HAYES GREGORY | Director | Grant | 796 | $0.00 | $0 | 796 |
| 2025-03-18 | Byrd Richard | EVP & President Interventional | Sell | 459 | $230.00 | $106K | 7K |
| 2025-03-12 | Byrd Richard | EVP & President Interventional | Sell | 2K | $224.91 | $436K | 7K |
| 2025-03-01 | Garrison Michael David | EVP & President Medical | Tax withholding | 178 | $0.00 | $0 | 5K |
| 2025-02-12 | SCOTT BERTRAM L | Director | Sell | 700 | $227.99 | $160K | 36K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON26 Form 144 notices on file for BDX worth $7.6M at the prices reported; 5 in the last 90 days worth $1.1M. Latest: MICHAEL FELD filed on 2026-10-26 to sell 76 shares ($15K) from 2026-10-26.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-26 | MICHAEL FELDOfficer | 76 | $15K | 0.000% | 2026-10-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-28 | MICHAEL FELDOfficer | 76 | $14K | 0.000% | 2026-09-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-26 | MICHAEL FELDOfficer | 165 | $31K | 0.000% | 2026-08-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-20 | RICHARD BYRDFormer Officer | 1K | $250K | 0.000% | 2026-08-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-13 | THOMAS POLENDirector, Officer | 4K | $762K | 0.002% | 2026-08-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-03 | SHANA NEALOfficer | 2K | $248K | 0.001% | 2026-08-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-27 | MICHAEL FELDOfficer | 75 | $12K | 0.000% | 2026-07-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-26 | MICHAEL FELDOfficer | 75 | $11K | 0.000% | 2026-06-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-24 | MICHAEL GARRISONOfficer | 1K | $158K | 0.000% | 2026-06-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-10 | MICHAEL GARRISONOfficer | 1K | $167K | 0.000% | 2026-06-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-01 | THOMAS POLENOfficer | 3K | $407K | 0.001% | 2026-06-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-26 | MICHAEL FELDOfficer | 75 | $11K | 0.000% | 2026-05-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-27 | MICHAEL FELDOfficer | 74 | $11K | 0.000% | 2026-04-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-26 | MICHAEL FELDOfficer | 75 | $14K | 0.000% | 2026-02-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-20 | DAVID MICHEL SHANFormer Officer | 5K | $998K | 0.002% | 2026-02-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-20 | CHRISTOPHER DELOREFICEFormer Officer | 11K | $2.1M | 0.004% | 2026-02-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-18 | CHRISTOPHER DELOREFICEFormer Officer | 9K | $1.7M | 0.003% | 2026-02-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-18 | BERTRAM SCOTTDirector | 953 | $174K | 0.000% | 2026-02-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-26 | MICHAEL FELDOfficer | 75 | $15K | 0.000% | 2026-01-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-15 | MICHAEL GARRISONOfficer | 2K | $334K | 0.001% | 2026-01-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-29 | MICHAEL FELDOfficer | 74 | $15K | 0.000% | 2025-12-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-17 | MICHAEL GARRISONOfficer | 629 | $124K | 0.000% | 2025-12-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-01 | MICHAEL FELDOfficer | 75 | $15K | 0.000% | 2025-12-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-07 | BERTRAM SCOTTOfficer | 217 | $38K | 0.000% | 2025-11-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-27 | MICHAEL FELDOfficer | 57 | $11K | 0.000% | 2025-10-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-26 | MICHAEL FELDOfficer | 58 | $10K | 0.000% | 2025-09-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON4 holders report 5% or more of BDX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Capital Management at 7.5% of the class (21,397,756 shares), filed 2026-04-29 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 15.0M | 5.4% | 2026-06-30 |
| 2026-08-06 | 13G | First Eagle Investment Management, LLCinvestment adviser | 14.1M | 5.1% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 1 | T. Rowe Price Investment Management, Inc.investment adviser | 9.7M | 3.4% | 2026-03-31 |
| 2026-04-29 | 13G | Vanguard Portfolio Managementinvestment adviser | 15.4M | 5.4% | 2026-03-31 |
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 21.4M | 7.5% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 14 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding BDX at their latest 13F. JSON5 of the 30 tracked managers held BDX at their latest 13F, $162.2M in total at quarter-end prices. AQR Capital Management is the largest at $98.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 650K | $98.1M | 0.03% | -108K |
| Two Sigma Investments | 2026-06-30 | 294K | $44.5M | 0.03% | +257K |
| Citadel Advisors | 2026-06-30 | 119K | $18.0M | 0.00% | -711K |
| Bridgewater Associates | 2026-06-30 | 9K | $1.4M | 0.01% | -114 |
| Fisher Asset Management | 2026-06-30 | 1K | $216K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q3 FY 2026 (quarter ended 2026-06-30) Becton, Dickinson reported revenue of $4.98B, up 5.4% from the same quarter a year earlier, and net income of $377.0M (1.37 diluted EPS). In FY 2025 it reported and spent $1.00B on buybacks and $1.20B on dividends. As of 2026-06-30, cash was $708.0M against $16.81B of debt.
- Cash
- $708.0M
- Debt
- $16.81B
- Equity
- $24.42B
- Total assets
- $50.73B
- Shares outstanding
- 272,386,800
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q3 FY 2026 | 2026-06-30 | $4.98B | $377.0M | 7.6% | 1.37 |
| Q2 FY 2026 | 2026-03-31 | $4.71B | -$311.0M | -6.6% | -1.11 |
| Q1 FY 2026 | 2025-12-31 | $5.25B | $382.0M | 7.3% | 1.34 |
| Q4 FY 2025derived | 2025-09-30 | $7.47B | $493.0M | 6.6% | n/a |
| Q3 FY 2025 | 2025-06-30 | $4.73B | $574.0M | 12.1% | 2.00 |
| Q2 FY 2025 | 2025-03-31 | $4.48B | $308.0M | 6.9% | 1.07 |
| Q1 FY 2025 | 2024-12-31 | $5.17B | $303.0M | 5.9% | 1.04 |
| Q4 FY 2024derived | 2024-09-30 | $5.44B | $400.0M | 7.4% | n/a |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-09-30 | $21.84B | $1.68B | n/a | $760.0M | $1.00B | $1.20B |
| FY 2024 | 2024-09-30 | $20.18B | $1.71B | n/a | $725.0M | $500.0M | $1.10B |
| FY 2023 | 2023-09-30 | $19.37B | $1.48B | n/a | $874.0M | $0 | $1.11B |
| FY 2022 | 2022-09-30 | $18.87B | $1.78B | n/a | $973.0M | $500.0M | $1.08B |
| FY 2021 | 2021-09-30 | $19.13B | $2.09B | $4.65B | $1.19B | $1.75B | $1.05B |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-06-30 from the cover page.
Federal contracts
The largest contract actions for Becton, Dickinson and its subsidiaries. JSON12 contract actions on file for BDX: $367K obligated in the last 90 days and $2.5M in the last 12 months across 3 awarding agencies. The largest was $561K from the Department of Health and Human Services on 2026-07-10 (bd facsdiscover s8 cell sorter). This covers the largest contract actions, not every award, and agencies report late.
| Action date | Agency | Amount | Type | Description |
|---|---|---|---|---|
| 2026-10-31 | Department of Health and Human ServicesFood and Drug Administration | $0 | mod P00001purchase order | FACSYMPHONY A5 SE WITH ANNUAL SERVICE OPTIONSUSAspending |
| 2026-10-30 | Department of Health and Human ServicesNational Institutes of Health | $250K | new awarddelivery order | REAGENT RENTAL AGREEMENTUSAspending |
| 2026-10-19 | Department of Veterans AffairsDepartment of Veterans Affairs | $41K | mod P00002definitive contract | BECTEC LAB ANALYZER SERVICES AND MAINTENANCE EO 14398USAspending |
| 2026-10-13 | Department of Veterans AffairsDepartment of Veterans Affairs | $33K | mod P00001purchase order | CPT PHOENIX AND BRUKER BASE PLUS 4USAspending |
| 2026-10-08 | Department of Veterans AffairsDepartment of Veterans Affairs | $25K | mod P00003purchase order | FACSLYRIC SERVICE AND UNIVERSAL LOADER SERVICEUSAspending |
| 2026-10-06 | Department of Veterans AffairsDepartment of Veterans Affairs | $18K | mod P00006purchase order | ADD FAR CLAUSE 52.222-90 ADDRESSING DEI DISCRIMINATION BY FEDERAL CONTRACTORS (APR 2026)USAspending |
| 2026-08-01 | Department of Health and Human ServicesNational Institutes of Health | $79K | new awardpurchase order | NIAID: SERVICE: SERVICE AGREEMENT FOR LSR FORTESSA AND FACS FLOW SUPPLY SYSTEM: SEVERABLEUSAspending |
| 2026-07-29 | Department of Veterans AffairsDepartment of Veterans Affairs | $490K | new awardpurchase order | BD FACSLYRIC IVD FLOW CYTOMETERSUSAspending |
| 2026-07-10 | Department of Health and Human ServicesNational Institutes of Health | $561K | new awardpurchase order | BD FACSDISCOVER S8 CELL SORTERUSAspending |
| 2026-07-10 | Department of Health and Human ServicesNational Institutes of Health | $283K | new awardpurchase order | NIAID: SERVICE: SERVICE AGREEMENT ON THE LABORATORY'S FLOW CYTOMETERS: SEVERABLEUSAspending |
| 2026-07-09 | Department of Health and Human ServicesNational Institutes of Health | $365K | new awardpurchase order | NIAID - RENEWAL SERVICE AGREEMENT FOR VARIOUS BD FLOW CYTOMETERS AND LASERSUSAspending |
| 2026-06-29 | Department of AgricultureAnimal and Plant Health Inspection Service | $398K | new awardpurchase order | PURCHASE OF FLOW CYTOMETRY INSTRUMENTUSAspending |
What this page is
Becton, Dickinson in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Becton, Dickinson (BDX), SEC CIK 10795, listed on NYSE, classified by the SEC as surgical & medical instruments & apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-26.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Federal contracts
- USAspending.govSource: USAspending.gov.The largest contract actions each day, as agencies report them (up to 90 days late). Latest 2026-10-31.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-26.JSON and CSV
- Company record
- EDGAR filing index for CIK 10795Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as surgical & medical instruments & apparatus
Other company pages
Datasets
Frequently Asked Questions
How much of BDX is sold short?
8,907,876 shares were held short at the 2026-10-15 settlement, 5.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is BDX's daily short volume?
On 2026-11-02, 183,753 of the 633,742 BDX shares reported to FINRA were sold short, 29.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does BDX have fails to deliver?
The SEC's latest file shows 2,869 BDX shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are BDX insiders buying or selling?
Insiders at BDX reported 5 open-market sells worth $1.3M in the last 90 days and no open-market buys. Latest filing: Feld Michael (EVP, Chief Revenue Officer) on 2026-10-26.
Have BDX insiders filed to sell?
26 Form 144 notices on file for BDX worth $7.6M at the prices reported; 5 in the last 90 days worth $1.1M. Latest: MICHAEL FELD filed on 2026-10-26 to sell 76 shares ($15K) from 2026-10-26.
Who owns 5% or more of BDX?
4 holders report 5% or more of BDX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Capital Management at 7.5% of the class (21,397,756 shares), filed 2026-04-29 for an event on 2026-03-31.
What did BDX report last quarter?
In Q3 FY 2026 (quarter ended 2026-06-30) Becton, Dickinson reported revenue of $4.98B, up 5.4% from the same quarter a year earlier, and net income of $377.0M (1.37 diluted EPS). In FY 2025 it reported and spent $1.00B on buybacks and $1.20B on dividends. As of 2026-06-30, cash was $708.0M against $16.81B of debt.
Which tracked 13F managers own BDX?
5 of the 30 tracked 13F managers held BDX shares at their latest filing, $162.2M in all. The largest: Cliff Asness's AQR Capital Management (650K shares, $98.1M), Two Sigma Investments (294K shares, $44.5M), Ken Griffin's Citadel Advisors (119K shares, $18.0M), Ray Dalio's Bridgewater Associates (9K shares, $1.4M), Ken Fisher's Fisher Asset Management (1K shares, $216K).
How much federal contract money did BDX receive?
$367K was obligated to Becton, Dickinson and its subsidiaries in the last 90 days and $2.5M in the last 12 months, counting the largest contract actions on USAspending, not every award. Obligations are not revenue; they are spent over each contract's life.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.